

### National Coverage Determination (NCD) on Medicare Coverage for Hepatitis B Virus (HBV) Screening

Effective October 1, 2016, the Centers for Medicare and Medicaid Services (CMS) released their final decision memo for the National Coverage Determination (NCD) on Medicare coverage for hepatitis B virus (HBV) screening. HBV screening in the primary care setting that is consistent with U.S. Preventive Services Task Force (USPSTF) recommendations will be covered for Medicare Part A and Part B beneficiaries who are pregnant or at high risk for infection.

High-risk populations are defined as:

- Persons born in countries and regions with a high prevalence of HBV infection (i.e.,  $\geq 2\%$ )
- United States-born persons not vaccinated as infants whose parents were born in regions with a very high prevalence of HBV infection (i.e.,  $\geq 8\%$ )
- HIV-positive persons
- Men who have sex with men (MSM)
- Persons who inject drugs (PWID)
- Household contacts or sexual partners of persons with HBV infection

CMS also determined that repeated HBV screening is appropriate annually for those with continued high risk (MSM, PWID, household contacts or sexual partners of persons with HBV infection) who have not received HBV vaccination. Repeat screening of pregnant women during each pregnancy is also covered, regardless of screening or vaccination history. This determination supports increased access to HBV screening for persons at risk and provides greater opportunities for diagnosis and linkage to HBV care.

Healthfirst providers who order the HBV screening for patients who meet the criteria above should refer those patients to a Healthfirst participating laboratory. To ensure the referring laboratory participates with Healthfirst, please visit [www.HFDocFinder.org](http://www.HFDocFinder.org).

## Provider Alerts

The applicable billing and diagnosis codes are **below**:

### BILLING: CPT codes covered if selection criteria are met:

<b>86704</b>	Hepatitis B core antibody (HBcAb); total
<b>86705</b>	IgM antibody
<b>86706</b>	Hepatitis B surface antibody (HBsAb)
<b>87340</b>	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; hepatitis B surface antigen (HBsAg)
<b>87341</b>	Hepatitis B surface antigen (HBsAg) neutralization

### DIAGNOSIS: ICD-10 codes covered if selection criteria are met:

<b>B20</b>	Human immunodeficiency virus [HIV] disease
<b>B97.35</b>	Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere
<b>F11.10 - F11.99</b>	Opioid related disorders [injecting drug users]
<b>F13.10 - F13.99</b>	Sedative, hypnotic, or anxiolytic related disorders [injecting drug users]
<b>F14.10 - F14.99</b>	Cocaine related disorders [injecting drug users]
<b>F15.10 - F15.99</b>	Other stimulant related disorders [injecting drug users]
<b>O10.011 - O16.9</b>	Edema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium
<b>O20.0 - O29.93</b>	Other maternal disorders predominantly related to pregnancy
<b>R74.0</b>	Nonspecific elevation of levels of transaminase or lactic acid dehydrogenase [LDH][ALT or AST]
<b>Z20.2</b>	Contact with and (suspected) exposure to infections with a predominantly sexual mode of transmission
<b>Z20.5</b>	Contact with and (suspected) exposure to viral hepatitis
<b>Z20.6</b>	Contact with and (suspected) exposure to human immunodeficiency virus [HIV]
<b>Z21</b>	Asymptomatic human immunodeficiency virus [HIV] infection status
<b>Z22.4</b>	Carrier of infections with a predominantly sexual mode of transmission
<b>Z22.50 - Z22.59</b>	Carrier of viral hepatitis
<b>Z34.00 - Z34.93</b>	Encounter for supervision of normal pregnancy
<b>Z51.11</b>	Encounter for antineoplastic chemotherapy
<b>Z72.51 - Z72.53</b>	High-risk sexual behavior
<b>Z94.0 - Z94.9</b>	Transplanted organ and tissue status
<b>Z99.2</b>	Dependence on renal dialysis

For additional information on this CMS National Coverage Determination (NCD), you may visit [www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=283](http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=283).